发明申请
- 专利标题: Anthrax antigenic compositions
- 专利标题(中): 炭疽抗原组合物
-
申请号: US10494384申请日: 2002-11-01
-
公开(公告)号: US20050112145A1公开(公告)日: 2005-05-26
- 发明人: Michael Hudson , Andrew Robinson , Nigel Silman , Bassam Hallis , Charles Penn
- 申请人: Michael Hudson , Andrew Robinson , Nigel Silman , Bassam Hallis , Charles Penn
- 优先权: GB0126266.6 20011101
- 国际申请: PCT/GB02/04985 WO 20021101
- 主分类号: C12N15/09
- IPC分类号: C12N15/09 ; A61K39/02 ; A61K39/07 ; A61K48/00 ; A61P31/04 ; C12N15/31 ; C12P21/02
摘要:
An antigenic pharmaceutical composition is provided comprising Protective Antigen (PA) and Lethal Factor (LF), wherein said PA and/or LF lacks a functional binding site, thereby preventing said PA and LF from binding together via said binding site or thereby preventing said PA from binding to a native PA cell receptor via said binding site, and wherein said composition is substantially non-toxic to animal cells. The composition is for preventing or minimising anthrax toxicity in mammals, preferably in humans. Also provided are DNA and RNA based vaccines encoding the antigenic components of said pharmaceutical composition. The present specification also describes antibodies that bind to at least one of PA, LF or EF, which binding thereby prevents:—(i) PA from binding to LF or EF, or to a native PA cell receptor; or (ii) LF from binding to PA; or (iii) EF from binding to PA.